<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371174">
  <stage>Registered</stage>
  <submitdate>28/07/2016</submitdate>
  <approvaldate>3/08/2016</approvaldate>
  <actrnumber>ACTRN12616001027404</actrnumber>
  <trial_identification>
    <studytitle>Vitamin D3 Absorption Studies in Healthy Adult Volunteers.</studytitle>
    <scientifictitle>Vitamin D3 Absorption Studies in Healthy Adult Volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D3 deficiency </healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To Evaluate the Absorption Efficacy Characteristics and Further Safety Over a 6-hour period in High Dose Vitamin D3 [5000 I.U administered as ONE dose] from SIX Preparations to Healthy Participants. ORAL delivery, ONE preparation per participant/day, for six days. Each of the six preparations will be administered to each participant in the same order across six consecutive days. Clinical Trial coordinator to oversee dose administered. 5000 I.U. at baseline of one of the following D3 preparations:
1) Metagenics 1000 IU/drop
2) Vitamin Shoppe 1 softgel=5000 IU
3) Solgar 1 veg cap=5000 IU
4) Nature's Way 1 softgel=5000 IU
5) Jarrow 1 softgel=5000 IU
6) InMed Technologies LLC 2 sprays=5000 IU</interventions>
    <comparator>Allocation; Non-Randomised; Self Control; Active Control; Primary Purpose: Absorption Characteristics of Vitamin D3 Preparations; Overall Study. Self control; participants will self administer dose and all SIX preparations are active. Sequential allocation to each preparation once the target sample size has been met.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absorption Characteristics ; plasma concentration of Vitamin D3
</outcome>
      <timepoint>Blood draws at t- 0 (baseline), 60, 180, 360 minutes. 4 time points/day over six consecutive days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety. Clinical Trial Coordinator to monitor participants and any adverse effects. Any adverse effects will be documented in the individuals Case Report Form. Side effects may include (but not limited to): headache, loss of appetite, dry mouth, nausea and vomitting. </outcome>
      <timepoint>Blood draws at t- 0 (baseline), 60, 180, 360 minutes. 4 time points/day over six consecutive days.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants &gt;18 years of age - 80 years of age at time of entry into the study;
1) No evidence or documented history of a chronic disease
2) Cognitive ability to understand informed consent process and to give informed consent to the experimental treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any clinically relevant abnormal findings which, in the opinion of the investigators/clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including;
1) Previous history of abnormal blood results i.e. FBE, U and E Liver Function Tests
2) Vital signs
3) The use of any nicotine products including;
i) nicotine patches/gum ii) tobacco smoking
4) Alcohol abuse
5) The use of any illicit drugs
6) Unstable angina not well managed with medication
7) Pregnancy or nursing of an infant
8) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant [i.e. suicide thoughts or euthanasia requests]</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>28/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/12/2016</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>13/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medlab Clinical</primarysponsorname>
    <primarysponsoraddress>66 McCauley Street, Alexandria, New South Wales, 2015</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medlab Clinical </fundingname>
      <fundingaddress>66 McCauley Street, Alexandria, New South Wales, 2015</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is significant interest from researchers, general practitioners and the public re: the administration of Vitamin D3 supplements for health maintenance or disease treatments. The aim of this study is to evaluate the absorption characteristics of a selected group of U.S. MARKETED OVER THE COUNTER (OTC) PRO-HORMONE (D3) PRODUCTS. These products are not commercially available in Australia. As such this study proposes to evaluate the absorption characteristics of these products. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Institute of Integrative Medicine </ethicname>
      <ethicaddress>11-23 Burwood Rd, Hawthorn, Melbourne VIC 3122</ethicaddress>
      <ethicapprovaldate>9/10/2013</ethicapprovaldate>
      <hrec>001/072013</hrec>
      <ethicsubmitdate>1/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical, 66 McCauley Street, Alexandria, New South Wales 2015</address>
      <phone>+61 (2) 8188 0311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Tessa Nikov</name>
      <address>Medlab Clinical, 66 McCauley Street, Alexandria, New South Wales 2015</address>
      <phone>+61 (2) 8188 0311</phone>
      <fax />
      <email>tessa_nikov@medlab.co</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical, 66 McCauley Street, Alexandria, New South Wales, 2015</address>
      <phone>+61 (2) 8188 0311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>